• NextCure agreed to merge with privately held Avere Therapeutics in an all-stock deal, with closing expected in 2H 2026.
• The combined company is expected to operate as Avere Therapeutics, trading on Nasdaq under ticker AVRX.
• Avere’s lead asset AVR-001 is a once-weekly oral IL-23 receptor antagonist in development for psoriasis, with Phase 1b data cited.
• A concurrent USD 320 million private placement includes USD 251 million of convertible notes to be exchanged for common stock at closing.
• Cash runway is expected to fund AVR-001 through a Phase 2b psoriasis readout, start of Phase 3 in psoriasis, start of Phase 2b in ulcerative colitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140600PRIMZONEFULLFEED9761703) on July 14, 2026, and is solely responsible for the information contained therein.